• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infect Drug Resist . Clinical Course and Risk Factors for Liver Injury of Severe and Critical Patients with COVID-19

tetano

Editor, Senior Moderator
Infect Drug Resist


. 2022 Dec 2;15:7025-7035.
doi: 10.2147/IDR.S380742. eCollection 2022.
Clinical Course and Risk Factors for Liver Injury of Severe and Critical Patients with COVID-19


Chunjing Du[SUP] #[/SUP][SUP] 1 [/SUP], Siyuan Yang[SUP] #[/SUP][SUP] 2 [/SUP], Chuansheng Li[SUP] 1 [/SUP], Pan Xiang[SUP] 1 [/SUP], Lin Pu[SUP] 1 [/SUP], Jingyuan Liu[SUP] 1 [/SUP]



Affiliations

Abstract

Introduction: Information regarding the clinical course of COVID-19 patients with liver injury is very limited, especially in severe and critical patients. The objective of this study was to describe the characteristics and clinical course of liver function in patients admitted with severe and/or critical SARS-CoV-2 infection, as well as explore the risk factors that affect liver function in the enrolled COVID-19 patients.
Methods: Information on clinical characteristics of 63 severe and critical patients with confirmed COVID-19 was collected. Data on patients' demographics, laboratory characteristics, laboratory examination, SARS-CoV-2 RNA results and liver test parameters were acquired and analyzed.
Results: The incidence of abnormal aspartate aminotransferase, alanine aminotransferase, and total bilirubin in the critical group was significantly higher than in the severe group (respectively 81.48%, 81.49%, 62.67%, and 45.71%, 63.88%, 22.86%, p < 0.05). The time for liver function parameters to reach their extremes was approximately 2-3 weeks after admission. The independent factors associated with liver injury were patients with invasive ventilators, decreased percentages of neutrophils, lymphocytes and monocytes, and sequential organ failure assessment (SOFA) score ≥2 (p < 0.05).
Conclusion: Abnormal liver tests are commonly observed in severe and critical patients with COVID-19. Severe patients infected by SARS-CoV-2 should be closely observed and monitored the liver function parameters, particularly when they present with independent risk factors for liver injury.

Keywords: COVID-19; SARS-CoV-2; abnormal liver tests; coronavirus disease 2019; liver injury; pneumonia; severe acute respiratory syndrome coronavirus 2.
 
Back
Top Bottom